356 related articles for article (PubMed ID: 23116118)
1. Development of a Gd(III)-based receptor-induced magnetization enhancement (RIME) contrast agent for β-glucuronidase activity profiling.
Chen SH; Kuo YT; Singh G; Cheng TL; Su YZ; Wang TP; Chiu YY; Lai JJ; Chang CC; Jaw TS; Tzou SC; Liu GC; Wang YM
Inorg Chem; 2012 Nov; 51(22):12426-35. PubMed ID: 23116118
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and characterization of a new bioactivated paramagnetic gadolinium(III) complex [Gd(DOTA-FPG)(H2O)] for tracing gene expression.
Chang YT; Cheng CM; Su YZ; Lee WT; Hsu JS; Liu GC; Cheng TL; Wang YM
Bioconjug Chem; 2007; 18(6):1716-27. PubMed ID: 17935289
[TBL] [Abstract][Full Text] [Related]
3. A Gd3+-based magnetic resonance imaging contrast agent sensitive to beta-galactosidase activity utilizing a receptor-induced magnetization enhancement (RIME) phenomenon.
Hanaoka K; Kikuchi K; Terai T; Komatsu T; Nagano T
Chemistry; 2008; 14(3):987-95. PubMed ID: 17992679
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of methotrexate-conjugated gadolinium(III) for cancer diagnosis and treatment.
Xu D; Lu ST; Li YS; Baidya A; Mei H; He Y; Wu B
Drug Des Devel Ther; 2018; 12():3301-3309. PubMed ID: 30323562
[TBL] [Abstract][Full Text] [Related]
5. Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular gd-chelate in a rat brain tumor model.
Fries P; Runge VM; Bücker A; Schürholz H; Reith W; Robert P; Jackson C; Lanz T; Schneider G
Invest Radiol; 2009 Apr; 44(4):200-6. PubMed ID: 19300099
[TBL] [Abstract][Full Text] [Related]
6. A gadolinium chelate for detection of beta-glucuronidase: a self-immolative approach.
Duimstra JA; Femia FJ; Meade TJ
J Am Chem Soc; 2005 Sep; 127(37):12847-55. PubMed ID: 16159278
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of novel macrocyclic and acyclic ligands as contrast enhancement agents for magnetic resonance imaging.
Chong HS; Garmestani K; Bryant LH; Milenic DE; Overstreet T; Birch N; Le T; Brady ED; Brechbiel MW
J Med Chem; 2006 Mar; 49(6):2055-62. PubMed ID: 16539394
[TBL] [Abstract][Full Text] [Related]
8. Gadolinium complex of DO3A-benzothiazole aniline (BTA) conjugate as a theranostic agent.
Kim HK; Kang MK; Jung KH; Kang SH; Kim YH; Jung JC; Lee GH; Chang Y; Kim TJ
J Med Chem; 2013 Oct; 56(20):8104-11. PubMed ID: 24063520
[TBL] [Abstract][Full Text] [Related]
9. A novel cholic acid-based contrast enhancement agent for targeted MRI.
Chong HS; Song HA; Lim S; Macrenaris K; Ma X; Lee H; Bui P; Meade T
Bioorg Med Chem Lett; 2008 Apr; 18(7):2505-8. PubMed ID: 18337094
[TBL] [Abstract][Full Text] [Related]
10. In vivo magnetic resonance imaging of mice liver tumors using a new gadolinium-based contrast agent.
Chen SH; Kuo YT; Cheng TL; Chen CY; Chiu YY; Lai JJ; Chang CC; Jaw TS; Wang YM; Liu GC
Kaohsiung J Med Sci; 2013 May; 29(5):246-53. PubMed ID: 23639510
[TBL] [Abstract][Full Text] [Related]
11. Cerebral blood volume quantification in a C6 tumor model using gadolinium per (3,6-anhydro) alpha-cyclodextrin as a new magnetic resonance imaging preclinical contrast agent.
Lahrech H; Perles-Barbacaru AT; Aous S; Le Bas JF; Debouzy JC; Gadelle A; Fries PH
J Cereb Blood Flow Metab; 2008 May; 28(5):1017-29. PubMed ID: 18183033
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, characterization, and pharmacokinetic evaluation of a potential MRI contrast agent containing two paramagnetic centers with albumin binding affinity.
Parac-Vogt TN; Kimpe K; Laurent S; Vander Elst L; Burtea C; Chen F; Muller RN; Ni Y; Verbruggen A; Binnemans K
Chemistry; 2005 May; 11(10):3077-86. PubMed ID: 15776492
[TBL] [Abstract][Full Text] [Related]
13. Gadolinium chelate with DO3A conjugated 2-(diphenylphosphoryl)-ethyldiphenylphosphonium cation as potential tumor-selective MRI contrast agent.
Chandrasekharan P; Yong CX; Poh Z; He T; He Z; Liu S; Robins EG; Chuang KH; Yang CT
Biomaterials; 2012 Dec; 33(36):9225-31. PubMed ID: 23026708
[TBL] [Abstract][Full Text] [Related]
14. [Gd-AAZTA]-: a new structural entry for an improved generation of MRI contrast agents.
Aime S; Calabi L; Cavallotti C; Gianolio E; Giovenzana GB; Losi P; Maiocchi A; Palmisano G; Sisti M
Inorg Chem; 2004 Nov; 43(24):7588-90. PubMed ID: 15554621
[TBL] [Abstract][Full Text] [Related]
15. Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action.
Caravan P
Acc Chem Res; 2009 Jul; 42(7):851-62. PubMed ID: 19222207
[TBL] [Abstract][Full Text] [Related]
16. In vivo labeling of B16 melanoma tumor xenograft with a thiol-reactive gadolinium based MRI contrast agent.
Menchise V; Digilio G; Gianolio E; Cittadino E; Catanzaro V; Carrera C; Aime S
Mol Pharm; 2011 Oct; 8(5):1750-6. PubMed ID: 21780833
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and characterization of HE-24.8: a polymeric contrast agent for magnetic resonance angiography.
Kiessling F; Heilmann M; Lammers T; Ulbrich K; Subr V; Peschke P; Waengler B; Mier W; Schrenk HH; Bock M; Schad L; Semmler W
Bioconjug Chem; 2006; 17(1):42-51. PubMed ID: 16417250
[TBL] [Abstract][Full Text] [Related]
18. GdIII complexes with fast water exchange and high thermodynamic stability: potential building blocks for high-relaxivity MRI contrast agents.
Laus S; Ruloff R; Tóth E; Merbach AE
Chemistry; 2003 Aug; 9(15):3555-66. PubMed ID: 12898682
[TBL] [Abstract][Full Text] [Related]
19. A Gd3Al tetranuclear complex as a potential bimodal MRI/optical imaging agent.
Li WS; Luo J; Jiang F; Chen ZN
Dalton Trans; 2012 Aug; 41(31):9405-10. PubMed ID: 22740063
[TBL] [Abstract][Full Text] [Related]
20. Extracellular biodegradable macromolecular gadolinium(III) complexes for MRI.
Lu ZR; Parker DL; Goodrich KC; Wang X; Dalle JG; Buswell HR
Magn Reson Med; 2004 Jan; 51(1):27-34. PubMed ID: 14705042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
